A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis
V Ratziu, V de Ledinghen, F Oberti, P Mathurin… - Journal of …, 2011 - Elsevier
BACKGROUND & AIMS: Nonalcoholic steatohepatitis (NASH) is a prevalent liver disease
associated with increased morbidity and mortality. Ursodeoxycholic acid (UDCA) may have
antioxidant, anti-inflammatory, and antifibrotic properties and may reduce liver injury in
NASH. To date, no studies have assessed the efficacy and safety of high-dose UDCA (HD-
UDCA) in patients with NASH. METHODS: We conducted a 12-month, randomized, double-
blind, placebo-controlled multicenter trial to evaluate the efficacy and safety of HD-UDCA …
associated with increased morbidity and mortality. Ursodeoxycholic acid (UDCA) may have
antioxidant, anti-inflammatory, and antifibrotic properties and may reduce liver injury in
NASH. To date, no studies have assessed the efficacy and safety of high-dose UDCA (HD-
UDCA) in patients with NASH. METHODS: We conducted a 12-month, randomized, double-
blind, placebo-controlled multicenter trial to evaluate the efficacy and safety of HD-UDCA …